E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ARDS due to COVID-19 necessitating invasive mechanical ventilation |
Invasive mechanische Beatmung bei ARDS aufgrund von COVID-19 |
|
E.1.1.1 | Medical condition in easily understood language |
acute lung failure and machine Ventilation due to COVID-19 |
Akutes Lungenversagen und maschinelle Beatmung aufgrund einer schweren COVID-19-Infektion |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084270 |
E.1.2 | Term | SARS-CoV-2 acute respiratory disease |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003083 |
E.1.2 | Term | ARDS |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assessment of impact of immune therapy with COVID-19 convalescent plasma on severity of COVID-19 |
Ermittlung des Einflusses einer Immuntherapie mit COVID-19-Rekonvaleszentenplasma auf den Schweregrad von COVID-19 |
|
E.2.2 | Secondary objectives of the trial |
Assessment of impact of immune therapy with COVID-19 convalescent plasma on • markers for ARDS due to severe COVID-19 infection. • short-term all-cause mortality. • time course of ARDS due to severe COVID-19. Assessment of safety and tolerability of immune therapy with COVID-19 convalescent plasma.
|
Ermittlung des Einflusses einer Immuntherapie mit COVID-19-Rekonvaleszentenplasma auf - ARDS-Marker verursacht durch schwere COVID-19-Infektion - Kurzzeit-Sterblichkeit - Zeitlicher Verlauf eines COVID-19-verursachten ARDS Ermittlung von Sicherheit und Verträglichkeit einer Immuntherapie mit COVID-19-Rekonvaleszentenplasma |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female subject aged ≥18 years. 2. Estimated BMI ≥19kg/m² to ≤40kg/m². 3. Florid SARS-CoV-2 infection confirmed by RT-PCR in tracheo-bronchial secretion sample or pharyngeal swab sample. 4. ARDS with Horovitz index <300mmHg. 5. Necessity of invasive mechanical ventilation. 6. Written informed consent obtained from the subject’s legal representative or under such arrangement as is legally acceptable in Germany (see Section 13.3). 7. Subject’s assent if obtainable.
|
1. Männliche oder weibliche Patienten ≥18 Jahre 2. BMI zwischen 19 und 40kg/m² 3. Floride SARS-CoV-2-Infektion, nachgewiesen durch RT-PCR aus Tracheobronchialsekret oder Rachenabstrich 4. ARDS mit einem Horovitz-Index < 300mmHg 5. Notwendigkeit einer invasiven mechanischen Beatmung 6. Schriftliche Einwilligung durch den gesetzlichen Vertreter oder unter sonstigen gesetzlich vorgesehenen Bedingungen 7. Assent des Patienten, sofern möglich |
|
E.4 | Principal exclusion criteria |
1. Adverse reaction to plasma proteins in medical history. 2. Interval >72h since endotracheal intubation. 3. Current or imminent necessity of ECMO treatment. 4. Pre-existing COPD GOLD stage 4. 5. Chronic congestive heart failure NYHA ≥3. 6. Pre-existing left ventricular ejection fraction <30%. 7. Liver cirrhosis Child-Pugh class C. 8. Acute liver failure with bilirubin >5x ULN and either ALT or AST >10x ULN. 9. Known congenital, selective severe deficiency of immunoglobulin A (IgA not detectable or close to detection Limit in contrast to other Ig). 10. Cardiovascular resuscitation in the 14 days prior to Screening Visit [V1]. 11. Organ or bone marrow transplant in the three months prior to Screening Visit [V1]. 12. Pregnancy. 13. Breastfeeding woman. 14. Previous exposure to COVID-19 convalescent plasma |
1. Unerwünschte Reaktion auf Plasmaproteine in der medizinischen Vorgeschichte 2. >72 Stunden seit endotrachealer Intubation 3. Laufende oder unmittelbar bevorstehende Notwendigkeit einer ECMO 4. Vorbestehende COPD GOLD-Stadium 4 5. Chronische Herzinsuffizient NYHA ≥3 6. Eingeschränkte linksventrikuläre Ejektionsfraktion <30% 7. Leberzirrhose Child-Pugh Klasse C 8. Akutes Leberversagen mit Bilirubin >5x ULN and entweder ALT oder AST >10x ULN 9. Bekannter angeborener, schwerer selektiver IgA-Mangel 10. Kardiopulmonale Wiederbelebung in den 14 Tagen vor Screening 11. Organ- oder Knochenmarkstransplantation in den drei Monaten von Screening 12. Schwangerschaft 13. Stillzeit 14. Frühere Exposition gegenüber COVID-19 Rekonvaleszentenplasma |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in SOFA score from Baseline Visit [Day 1, Visit 2] to Day 8 [Visit 9] |
Änderung des SOFA-Scores von Baseline (Visite 2) bis Tag 8 (Visite 9)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 8 (Visit 9) |
Tag 8 (Visite 9) |
|
E.5.2 | Secondary end point(s) |
- SOFA score: Mean change from Baseline Visit [Day 1, Visit 2] to all subsequent visits until and including Day 29 [Visit 15] or until extubation, whichever comes first - Rescue therapy: Number and proportion of subjects without rescue therapy until and including Day 8 [Visit 9] - ECMO: Mean number of days without ECMO during the period from Baseline Visit [Day 1, Visit 2] until and including Day 8 [Visit 9], Day 15 [Visit 13], and Day 29 [Visit 15], per treatment group and per subject - Invasive mechanical ventilation parameters and endotracheal Intubation: Mean number of days without invasive mechanical ventilation during the period from Baseline Visit [Day 1, Visit 2] until and including Day 8 [Visit 9], Day 15 [Visit 13], and Day 29 [Visit 15], per treatment group and per subject - Survival: Number and proportion of subjects having died until and including Day 29 [Visit 15] and End of Study Visit [Day 61±3 days, Visit 16] - Safety: Cumulated number and proportion of subjects with AE, AR, SAE, SAR, and SUSAR from Baseline Visit [Day 1, Visit 2] until and including Day 11 [Visit 12] |
- SOFA-Score: Mittelwert der Änderung von Baseline im Vergleich zu allen darauffolgenden Visiten bis einschließlich Tag 29 (Visite 15) oder zum Zeitpunkt der Extubation - Rescue-Therapie: Anzahl und Anteil der Studienteilnehmer, die bis Ende Tag 8 (Visite 9) keine Rescue-Therapie benötigen - ECMO: Durchschnittliche Anzahl der Tage ohne ECMO im Zeitraum von Baseline bis einschließlich Ende Tag 8 (Visite 9), Tag 15 (Visite 13) und Tag 29 (Visite 15), getrennt nach Behandlungsarm und pro Studienteilnehmer - Invasive mechanische Beatmung: Durchschnittliche Anzahl von Tagen ohne invasive mechanische Beatmung im Zeitraum von Baseline bis einschließlich Ende Tag 8 (Visite 9), Tag 15 (Visite 13) und Tag 29 (Visite 15), getrennt nach Behandlungsarm und pro Studienteilnehmer - Überleben: Anzahl und Anteil an Studienteilnehmern, die bis einschließlich Tag 29 (Visite 15) und EOS (Tag 61±3 Tage, Visite 16) versterben - Safety: Kumulative Anzahl und Anteil an Studienteilnehmer mit AE, AR, SAE, SAR, und SUSAR von Baseline bis einschließlich Tag 11 (Visite 12) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline until EOS (day 61 -3/+21 days) |
Baseline bis End of study (Tag 61 -3/+21 Tage) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standardbehandlung |
standard treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
date when the last subject has completed Visit 16 (day 61 +/- 3 days; EOS) or the date of the last visit of the last subject should that subject drop out earlier for other reasons, respectively |
Datum, zu dem der letzte Teilnehmer Visit 16 (Tag 61 +/- Tage; EOS) komplettiert hat bzw. Datum der letzten Visite des letzten Studienteilnehmers, sofern dieser vor Visite 16 ausgeschieden ist. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |